2022
Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study
Cox H, Goig GA, Salaam-Dreyer Z, Dippenaar A, Reuter A, Mohr-Holland E, Daniels J, Cudahy PGT, Nicol MP, Borrell S, Reinhard M, Doetsch A, Beisel C, Gagneux S, Warren RM, Furin J. Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study. Journal Of Clinical Microbiology 2022, 60: e02362-21. PMID: 35170980, PMCID: PMC8925891, DOI: 10.1128/jcm.02362-21.Peer-Reviewed Original ResearchConceptsDrug susceptibility testingRifampicin-resistant tuberculosisShort regimenMDR/RR-TB patientsMDR/RR-TBRR-TB patientsRetrospective cohort studyMore effective treatment regimensHigh-burden settingsRoutine drug susceptibility testingTB drug resistanceEffective treatment regimensWhole-genome sequencingTolerable regimensCohort studyRetrospective cohortRR-TBRegimen changeTreatment regimensTreatment recommendationsPatient outcomesTreatment individualizationClinical dataIndividualized treatmentIneffective drugs
2021
Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa
Salaam-Dreyer Z, Streicher EM, Sirgel FA, Menardo F, Borrell S, Reinhard M, Doetsch A, Cudahy PGT, Mohr-Holland E, Daniels J, Dippenaar A, Nicol MP, Gagneux S, Warren RM, Cox H. Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa. Antimicrobial Agents And Chemotherapy 2021, 65: 10.1128/aac.00364-21. PMID: 34460307, PMCID: PMC8522772, DOI: 10.1128/aac.00364-21.Peer-Reviewed Original ResearchConceptsMultidrug-resistant TBRMR-TBRR-TBPatient-level clinical dataPhenotypic drug susceptibility testingRifampicin-monoresistant tuberculosisRR-TB patientsMultidrug-resistant tuberculosisHIV-positive individualsRifampin-resistant tuberculosisDrug susceptibility testingRifampin monoresistanceHIV infectionMDR isolatesTB drugsRisk factorsClinical dataSusceptibility testingSubset of isolatesTuberculosisDescriptive studyMycobacterium tuberculosisAvailable WGS dataSignificant differencesPatients